Kevin Outterson, JD, LLM
Professor of Law and N. Neal Pike Scholar
Boston University School of Law
Dept of Health and Disability Law

LLM, University of Cambridge
JD, Northwestern University

Research interests in pharmaceutical innovation, including the law & economics of antimicrobial resistance.

Associate Professor
Boston University School of Public Health
Health Law, Policy & Management

Executive Director
Boston University School of Law
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)

WT CARB-X PD Costs Cost-Share
04/01/2017 - 07/31/2021 (PI)
Wellcome Trust

WT CARB-X Non Awardee Costs
04/01/2017 - 07/31/2018 (PI)
Wellcome Trust

08/01/2016 - 07/31/2018 (PI)
HHS/Assistant Secretary for Preparedness
6 IDSEP160030-01-03

Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2017 Dec 21. PMID: 29276051.
  2. Theuretzbacher U, Savic M, Årdal C, Outterson K. Market watch: Innovation in the preclinical antibiotic pipeline. Nat Rev Drug Discov. 2017 Nov; 16(11):744-745. PMID: 28983100.
  3. Barlam TF, Morgan JR, Kaplan WA, Outterson K, Pelton SI. Disproportionate Exposure to Antibiotics in Children at Risk for Invasive Pneumococcal Disease: Potential for Emerging Resistance and Opportunity for Antibiotic Stewardship. J Pediatric Infect Dis Soc. 2017 Sep 07.View Related Profiles. PMID: 28992176.
  4. Årdal C, Baraldi E, Ciabuschi F, Outterson K, Rex JH, Piddock LJV, Findlay D. To the G20: incentivising antibacterial research and development. Lancet Infect Dis. 2017 Aug; 17(8):799-801. PMID: 28689703.
  5. Deak D, Powers JH, Outterson K, Kesselheim AS. The Fight Against Multidrug-Resistant Bacteria. Ann Intern Med. 2017 01 03; 166(1):79. PMID: 28030672; DOI: 10.7326/L16-0582;.
  6. Outterson K, McDonnell A. Antimicrobial Resistance: The Authors Reply. Health Aff (Millwood). 2016 Oct 01; 35(10):1936. PMID: 27702975.
  7. Outterson K, Rex JH, Jinks T, Jackson P, Hallinan J, Karp S, Hung DT, Franceschi F, Merkeley T, Houchens C, Dixon DM, Kurilla MG, Aurigemma R, Larsen J. Accelerating global innovation to address antibacterial resistance: introducing CARB-X. Nat Rev Drug Discov. 2016 09; 15(9):589-90. PMID: 27469032; DOI: 10.1038/nrd.2016.155;.
  8. Outterson K, Gopinathan U, Clift C, So AD, Morel CM, Røttingen JA. Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality. PLoS Med. 2016 Jun; 13(6):e1002043. PMID: 27299990; PMCID: PMC4907461; DOI: 10.1371/journal.pmed.1002043;.
  9. Deak D, Outterson K, Powers JH, Kesselheim AS. Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015. Ann Intern Med. 2016 Sep 06; 165(5):363-72. PMID: 27239977; DOI: 10.7326/M16-0291;.
  10. Outterson K, McDonnell A. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy. Health Aff (Millwood). 2016 May 01; 35(5):784-90. PMID: 27140983; DOI: 10.1377/hlthaff.2015.1139;.
Showing 10 of 37 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 37 publications over 14 distinct years, with a maximum of 6 publications in 2016

Contact for Mentoring:

765 Commonwealth Ave
Boston MA 02215
Google Map

Outterson's Networks
Click the "See All" links for more information and interactive visualizations
Similar People